MYMD vs. NAVB, VRAX, TRIB, BMRA, VRPX, OPGN, BSGM, LIPO, GNPX, and PXMD
Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Virax Biolabs Group (VRAX), Trinity Biotech (TRIB), Biomerica (BMRA), Virpax Pharmaceuticals (VRPX), OpGen (OPGN), BioSig Technologies (BSGM), Lipella Pharmaceuticals (LIPO), Genprex (GNPX), and PaxMedica (PXMD). These companies are all part of the "medical" sector.
MyMD Pharmaceuticals (NASDAQ:MYMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
Navidea Biopharmaceuticals' return on equity of 0.00% beat MyMD Pharmaceuticals' return on equity.
Navidea Biopharmaceuticals has higher revenue and earnings than MyMD Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, MyMD Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for MyMD Pharmaceuticals and 1 mentions for Navidea Biopharmaceuticals. MyMD Pharmaceuticals' average media sentiment score of 1.87 beat Navidea Biopharmaceuticals' score of 0.00 indicating that MyMD Pharmaceuticals is being referred to more favorably in the media.
9.6% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 2.6% of MyMD Pharmaceuticals shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
MyMD Pharmaceuticals and Navidea Biopharmaceuticals both received 0 outperform votes by MarketBeat users.
MyMD Pharmaceuticals has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
Summary
MyMD Pharmaceuticals beats Navidea Biopharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get MyMD Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
MyMD Pharmaceuticals Competitors List
Related Companies and Tools